Adaptimmune Therapeutics PLC (ADAP)
NASDAQ
News
Market Data
Customized watchlists with full streaming quotes from leading exchanges, such as NASDAQ, NYSE, AMEX, OTC Markets Small-Cap, LSE and more.
The current ADAP market cap is 1.11B. The company's latest EPS is USD -0.1026 and P/E is -9.65.
| Quarter End | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 |
|---|---|---|---|---|---|
| USD ($) | USD ($) | USD ($) | USD ($) | USD ($) | |
| Total Revenue | 47.6M | 5.13M | 7.32M | 231k | 5.68M |
| Operating Income | 1.55M | -22.94M | -46.3M | -28.32M | -49.02M |
| Net Income | 1.04M | -21.39M | -45.6M | -47.92M | -48.5M |
| Year End December 30 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD ($) | USD ($) | USD ($) | USD ($) | USD ($) | |
| Total Revenue | 1.12M | 3.96M | 6.15M | 27.15M | 60.28M |
| Operating Income | -138.62M | -133.58M | -157.85M | -166.4M | -118.3M |
| Net Income | -137.17M | -130.09M | -158.09M | -165.46M | -113.87M |
| Quarter End | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 |
|---|---|---|---|---|---|
| USD ($) | USD ($) | USD ($) | USD ($) | USD ($) | |
| Total Assets | 288.08M | 342.98M | 296.64M | 282.62M | 258.01M |
| Total Liabilities | 204.21M | 216.33M | 208.51M | 243.1M | 233.64M |
| Total Equity | 83.88M | 126.65M | 88.13M | 39.51M | 24.38M |
| Year End December 30 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD ($) | USD ($) | USD ($) | USD ($) | USD ($) | |
| Total Assets | 181.54M | 451.14M | 469.55M | 328.92M | 282.62M |
| Total Liabilities | 57.91M | 109.92M | 263.59M | 247.04M | 243.1M |
| Total Equity | 123.64M | 341.23M | 205.96M | 81.88M | 39.51M |
| Quarter End | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 |
|---|---|---|---|---|---|
| USD ($) | USD ($) | USD ($) | USD ($) | USD ($) | |
| Operating | -37.28M | -81.05M | -126.2M | -140.88M | -31.95M |
| Investing | 48.34M | 51.04M | 108.34M | 176.54M | -358k |
| Financing | 196k | 210k | 806k | 880k | 29.24M |
| Year End December 30 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD ($) | USD ($) | USD ($) | USD ($) | USD ($) | |
| Operating | -112.51M | -53.59M | 10.73M | -141.77M | -140.88M |
| Investing | 94.95M | -278.92M | 75.8M | 89.14M | 176.54M |
| Financing | 366k | 340.05M | 3.29M | 12.87M | 880k |
| Market Cap | 1.11B |
| Price to Earnings Ratio | -9.65 |
| Price to Sales Ratio | 18.23 |
| Price to Cash Ratio | 7.63 |
| Price to Book Ratio | 27.8 |
| Dividend Yield | - |
| Shares Outstanding | 1.11B |
| Average Volume (1 week) | 0 |
| Average Volume (1 Month) | 0 |
| 52 Week Change | - |
| 52 Week High | - |
| 52 Week Low | - |
| Spread (Intraday) | 0.53 (39.26%) |
| Company Name | Adaptimmune Therapeutics PLC |
| Address |
60 jubilee avenue oxfordshire OX14 4RX |
| Website | https://www.adaptimmune.com |
| Industry | pharmaceutical preparations (2834) |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
